Biosortia Pharmaceuticals, Inc. focused efforts as drug discovery company in 2012. During
2012-14 the company worked hard to adapt and advance the original AVS technology for the in
situ recovery of microorganisms. Proof and technological improvement of deep access to the
dark chemical material of secondary metabolites were conducted by our scientists simultaneously.
The original technology was supported by ARPA-E (Advanced Research Project Agency of the
U.S. Department of Energy) during 2009-2011.
By the mid-2015, the company completed of the final designs of the proprietary harvesting technology along with the construction of a full-scale system. Biosortia’s team recognized the historical success of finding drug-like compounds from the minuscule number of culturable micro-organisms (the 1%) and believed a substantial increase in access to unculturable microorganisms (the 99%) would equate to more opportunities to find new drugs. The belief was simple: if you could recover unculturable microorganisms on a scale to obtain the actual chemistry, it would open the door to discovery, much like the Hubble telescope opened the doors to the previously unseen Universe.
Biosortia unlocks the aquatic microbial environment, the new drug frontier of discovery in a new and completely different strategy than researchers have ever pursued.